If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBreedon Regulatory News (BREE)

Share Price Information for Breedon (BREE)

Share Price is delayed by 15 minutes
Get Live Data
292.00    -18.00 (-5.81%)
Bid:
292.00
Ask:
292.60
Spread: 0.60 (0.205%)
Market Cap: £1.01b
BREE Live PriceLast checked at - London Stock Exchange

Intraday Breedon Share Chart

Statement re Reverse Accelerated Bookbuild

9 Mar 2023 16:56

RNS Number : 4955S
Deutsche Bank AG, Frankfurt
09 March 2023
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR FORM PART OF AN OFFER TO BUY, SELL, ISSUE, ACQUIRE OR SUBSCRIBE FOR, OR THE SOLICITATION OF AN OFFER TO BUY, SELL, ISSUE, ACQUIRE OR SUBSCRIBE FOR, ANY SECURITIES IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER JURISDICTION.

 

FOR IMMEDIATE RELEASE

 

09 March 2023

 

Abicad Holding Limited announces intentionto acquire additional shares

of Breedon Group plc ("Breedon")

 

 

Abicad Holding Limited ("Abicad") announces its intention to acquire additional ordinary shares of Breedon at a price of 75 pence per share via a reverse accelerated bookbuild (the "RABB").

 

Abicad currently holds approximately 10% of Breedon's total issued share capital. Its current board representative is Amit Bhatia, who is the Non-executive Chairman of Breedon.

 

Abicad is a long-term investor in Breedon and intends to hold its shares (including any additional shares acquired pursuant to the RABB) for investment purposes. Abicad has been a supportive shareholder of Breedon since the transformational acquisition of Hope Construction Materials in 2016.

 

The purchase of additional shares in this transaction, which it is willing to make in an amount of up to 84.7 million ordinary shares (equivalent to approximately 5% of Breedon's total issued share capital), is a signal of Abicad's continued belief in the business and Breedon's overall strategic direction.

 

Abicad confirms that it is not intending to make an offer for Breedon. This is a statement to which Rule 2.8 of the Takeover Code (the "Code") applies.

 

Deutsche Bank Aktiengesellschaft ("Deutsche Bank") is acting as Sole Bookrunner for the RABB on behalf of Abicad.

 

The opportunity to participate in the RABB will be made available to certain professional investors outside the United States. The bookbuilding for the RABB will commence immediately following this announcement and may be closed at any time at the sole discretion of Deutsche Bank and Abicad. The final number of shares to be purchased will be agreed at the close of the RABB process at the sole discretion of Abicad and Deutsche Bank, and the results of the RABB will be announced as soon as practicable thereafter. To the extent that the RABB is oversubscribed, applications will be scaled back (whether on a pro rata basis or otherwise) at the sole discretion of Abicad and Deutsche Bank. The reverse accelerated bookbuilding procedure enables executing the repurchase of the Shares in a rapid and cost-efficient manner.

 

Rule 2.8 notes

 

Except with the consent of the Panel on Takeovers and Mergers (the "Takeover Panel"), Abicad is prohibited from announcing an offer or possible offer for Breedon and from taking certain other actions as set out in Rule 2.8 of the Code for a period of six months from the date of this announcement.

 

Under Note 2 on Rule 2.8 of the Code, Abicad reserves the right to set the restrictions in Rule 2.8 aside in the following circumstances: (a) with the agreement of the Board of Breedon; (b) if a third party announces a firm intention to make an offer for Breedon; (c) if Breedon announces a Rule 9 waiver proposal (see Note 1 of the Notes on Dispensations from Rule 9) or a reverse takeover (as defined in the Code); and (d) if there has been a material change of circumstances (as determined by the Takeover Panel).

 

For further information contact:

 

Deutsche Bank Aktiengesellschaft (Sole Bookrunner)

 

Stephane Gruffat

Mark Hankinson

Simon Hollingsworth

Parag Manudhane

 

 

 

Tel: +44 (0) 207 545 8000

 

 

IMPORTANT NOTICES

 

This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution is unlawful. This announcement is for information purposes only and the information contained herein does not constitute or form part of an offer to buy, sell, issue, acquire or subscribe for, or the solicitation of an offer to buy, sell, issue, acquire or subscribe for, any securities in the United States, Australia, Canada, Japan or in any other jurisdiction, nor shall there be any offer, solicitation, sale or purchase of securities in any jurisdiction in which such offer, solicitation, sale or purchase would be unlawful. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions.

 

This announcement is not an offer of securities for sale into the United States. The securities of Breedon have not or will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration.

 

The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction.

 

The RABB is not being directed, directly or indirectly, to Breedon investors located in the United States of America, or to agents, nominees, trustees, custodians or other persons acting for the account or benefit of such U.S. shareholders, or in any other jurisdiction where to do so would be unlawful.

 

This announcement is only directed at (and is only being distributed to persons outside the United States who are) (i) persons in any member state of the European Economic Area who are qualified investors ("Qualified Investors") within the meaning of Article 2 of the Prospectus Regulation (Regulation (EU) 2017/1129 of 14 June 2017) (and amendments thereto to the extent implemented in the relevant member state); or (ii) persons in the United Kingdom who are both (A) investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"); or (B) high net worth companies, or persons to whom it can otherwise be lawfully distributed, falling within the meaning of Article 49(2)(a) to (d) of the Order; and (C) qualified investors as defined in Article 2 of the UK Prospectus Regulation (Regulation (EU) 2017/1129 of 14 June 2017 as it has effect in the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018) (such persons referred to in this sub-paragraph (ii) being "relevant persons"). This release must not be acted on or relied on (a) in the United Kingdom, by persons who are not relevant persons, or (b) in any member state of the European Economic Area, by persons who are not Qualified Investors, or (c) elsewhere, by persons who are not permitted to sell or dispose of securities in the RABB pursuant to applicable legislation.

 

Any investment or investment activity referred to in this announcement is only available to, and will only be engaged in with, (1) relevant persons, in the United Kingdom; (2) Qualified Investors, in any member state of the European Economic Area; and (3) persons elsewhere who are permitted to sell or dispose of securities in the RABB pursuant to applicable legislation. Deutsche Bank reserves the absolute right to determine who may participate in the RABB.

 

Participating in the RABB shall constitute an irrevocable offer by such participant to sell to Abicad the total number of shares accepted for purchase from that participant by Deutsche Bank on behalf of Abicad. Investors offering shares for purchase in the RABB will be deemed to represent, warrant and undertake to Deutsche Bank and Abicad that: (a) the investor is the legal and beneficial owner and has full power and authority to sell, assign or transfer the shares being sold in the RABB (together with all rights attaching thereto) and, when the same are purchased by Abicad, Abicad will acquire such shares free and clear of all liens, charges, restrictions, claims, equitable interests, encumbrances, pre-emption rights and third party rights and together with all rights attaching thereto and such representation and warranty will be true in all respects at the time Abicad purchases such shares as if it had been entered into anew at such time and shall not be extinguished by such purchase; (b) such investor shall do all such acts and things as shall be necessary or expedient, and execute any additional documents deemed by Deutsche Bank or Abicad to be desirable, to complete the purchase of the shares referred to in this paragraph; (c) such investor has fully observed any applicable legal requirements, the RABB may be made to him under the laws of all relevant jurisdictions, and the investor's offer to sell shares to Abicad, and any acceptance thereof, shall not be unlawful under the laws of any jurisdiction. Deutsche Bank shall be under no obligation to purchase any shares in the RABB if its arrangements with Abicad terminate.

 

No document soliciting intentions to sell securities has been or will be prepared in connection with any of the transactions described in this announcement. Any investment decision to sell securities as part of the RABB must be made solely on the basis of publicly available information. Such information is not the responsibility of, and has not been independently verified by, Deutsche Bank or Abicad or any of their respective affiliates.

 

Deutsche Bank Aktiengesellschaft is authorised under German Banking Law (competent authority: European Central Bank). It is subject to supervision by the European Central Bank and by BaFin, Germany's Federal Financial Supervisory Authority. Deutsche Bank Aktiengesellschaft is a joint stock corporation incorporated with limited liability in the Federal Republic of Germany, with its head office in Frankfurt am Main where it is registered in the Commercial Register of the District Court under number HRB 30 000.

 

Deutsche Bank is acting exclusively for Abicad and no other person in connection with the RABB. Deutsche Bank will not regard any other person as its client in relation to the RABB and will not be responsible to any other person for providing the protections afforded to its clients, nor for providing advice in relation to the contents of this announcement or any transaction, arrangement or other matter referred to herein (including, without limitation, the RABB).

 

Neither Deutsche Bank nor any of its affiliates nor any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to, the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to Abicad or Breedon or any of its or their subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRUKVNROUUORAR
Date   Source Headline
7th Jul 20217:00 amRNSBlock listing Update
1st Jul 20216:16 pmRNSTotal Voting Rights
1st Jun 20213:49 pmRNSStandard form for notification of major holdings
1st Jun 20217:00 amRNSAcquisition
28th May 202110:02 amRNSTotal Voting Rights
7th May 20219:28 amRNSStandard form for notification of major holdings
23rd Apr 20211:46 pmRNSDirectors’ and PDMRs’ Dealings
23rd Apr 20211:37 pmRNSPDMR Dealings
20th Apr 20212:36 pmRNSResult of AGM
20th Apr 20217:00 amRNSAGM Trading Update
1st Apr 202111:04 amRNSGrant of SAYE Options and PDMR Dealings
1st Apr 20217:00 amRNSBoard Update
23rd Mar 202111:13 amRNSDirector Dealings
23rd Mar 202111:09 amRNS2020 Annual Report and Notice of AGM
10th Mar 20217:01 amRNSDirectorate Change
10th Mar 20217:00 amRNSAnnual Results 2020
26th Feb 20219:15 amRNSTotal Voting Rights
22nd Jan 20211:55 pmRNSDirector/PDMR Shareholding
22nd Jan 20218:46 amRNSAdditional Block Listing of Ordinary Shares
13th Jan 20217:00 amRNSAppointment of Corporate Broker
7th Jan 20212:45 pmRNSBlock listing Interim Review
23rd Dec 20207:00 amRNSTotal Voting Rights
21st Dec 20207:00 amRNSTrading Update
3rd Dec 20207:00 amRNSUpdate on CMA's Review of Completed Acquisition
2nd Dec 20203:55 pmRNSHolding(s) in Company
1st Dec 20204:50 pmRNSHolding(s) in Company
1st Dec 20207:10 amRNSUpdate on CMA's Review of Completed Acquisition
30th Nov 20201:31 pmRNSTotal Voting Rights
24th Nov 20204:55 pmRNSHolding(s) in Company
24th Nov 20207:00 amRNSDirectorate Change
18th Nov 20207:00 amRNSTrading Update
9th Nov 20207:00 amRNSAcquisition update
30th Oct 20207:00 amRNSTotal Voting Rights
6th Oct 20207:00 amRNSDirectorate Change
30th Sep 20207:00 amRNSTotal Voting Rights
17th Sep 20207:00 amRNSTrading Update
10th Sep 20207:13 amRNSCMA's Review of Completed Acquisition
7th Sep 202012:50 pmRNSGrant of SAYE Options and PDMR Dealings
27th Aug 20202:53 pmRNSDirectors' and PDMRs' Dealings
26th Aug 20207:14 amRNSCMA's Review of Proposed Acquisition
19th Aug 20205:30 pmRNSHolding(s) in Company
19th Aug 20205:30 pmRNSHolding(s) in Company
13th Aug 20204:09 pmRNSDirector and PDMR Dealings
3rd Aug 20207:00 amRNSCompletion of acquisition
31st Jul 20207:00 amRNSTotal Voting Rights
29th Jul 20207:00 amRNSHalf-year Report
8th Jul 20207:00 amRNSBlock listing Interim Review
6th Jul 202010:30 amRNSHolding(s) in Company
6th Jul 202010:30 amRNSHolding(s) in Company
19th Jun 20203:41 pmRNSDirector and PDMR Dealings & Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.